Nursing care
Diabetic Nephropathy nursing care: what to assess and what to do first
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Diabetic nephropathy is kidney damage from chronic hyperglycemia, and its earliest sign is microalbuminuria, small amounts of albumin in the urine that appear years before serum creatinine rises. Nursing care centers on catching that early marker, supporting tight glucose and blood pressure control, and understanding why an ACE inhibitor is started for kidney protection even when blood pressure is normal.
The clinical picture
Diabetic nephropathy develops slowly, often over ten to fifteen years, as chronically elevated glucose damages the glomerular capillaries and thickens the basement membrane. The kidney's filtering units lose their ability to hold onto protein before they lose their ability to clear waste, which is why the earliest laboratory change is protein leaking into the urine, not a rise in creatinine or BUN.
By the time creatinine climbs and GFR falls, meaningful kidney damage has already occurred. This is the core clinical fact that shapes everything else about care: nephropathy is silent in its early stage, and the patient feels nothing different while the damage accumulates. There is no pain, no change in urine output, no symptom that prompts the patient to seek care on their own.
Assessment: what to look for and in what order
Screen for microalbuminuria first, using a urine albumin-to-creatinine ratio, in every patient with type 1 diabetes of five or more years' duration and in every patient with type 2 diabetes starting at diagnosis, since the onset of type 2 is often unclear. This test catches the problem years before creatinine or GFR would show anything abnormal.
Once microalbuminuria is identified or nephropathy is established, monitor blood pressure closely, since hypertension both drives and accelerates glomerular damage in a self-reinforcing cycle. Track serum creatinine and estimated GFR over time rather than as a single value, because the trend, not one number, shows whether the kidney is declining. Review the patient's glucose control, since sustained hyperglycemia is the upstream driver of the vascular damage.
Immediate interventions
Confirm the patient is on an ACE inhibitor or ARB as soon as microalbuminuria is detected, regardless of whether blood pressure is elevated. This is a point that catches many students off guard: the drug is started for its effect on intraglomerular pressure and protein leakage, not to treat hypertension, so a normal blood pressure reading is not a reason to hold or question the order.
Monitor potassium after starting an ACE inhibitor or ARB, since both drug classes can cause hyperkalemia, particularly in a patient whose kidney function is already compromised. Reinforce tight glucose control per the current care plan, since bringing glucose closer to target slows further glomerular damage. Review the medication list for nephrotoxic agents, particularly NSAIDs, which many patients take for pain without recognizing the risk to already-vulnerable kidneys.
Ongoing nursing management
Support a reduced-sodium, moderate-protein diet as directed, since excess protein intake increases the kidney's filtration workload and excess sodium worsens the hypertension that drives further damage. Coordinate regular monitoring of the albumin-to-creatinine ratio, blood pressure, and renal function labs at the intervals the care plan specifies, since nephropathy is managed by trend over months and years, not by any single visit.
Watch for the later signs that appear once nephropathy progresses: rising blood pressure that becomes harder to control, edema as protein loss increases, and eventually a falling GFR. Coordinate with the provider on referral to nephrology once GFR drops below the threshold the practice uses, and prepare the patient for the possibility of dialysis planning if decline continues, without introducing that conversation earlier than the clinical picture warrants.
Patient and family education
Explain why the annual or more frequent urine microalbumin test matters even when the patient feels completely well: this is a disease that is caught early only through screening, not through symptoms. A patient who understands this is far more likely to keep the appointment.
Teach the patient that the ACE inhibitor or ARB protects the kidney directly, separate from blood pressure control, so they understand why the prescription continues even if their home blood pressure readings look normal. Reinforce that glucose control and blood pressure control work together to slow kidney damage, and that skipping either undermines the other. Cover the sodium and protein guidance in concrete terms, such as reading labels for sodium content, rather than abstract dietary principles.
How this appears on the NCLEX
Questions commonly test whether the student knows the correct screening test and its timing: urine albumin-to-creatinine ratio, checked annually from diagnosis in type 2 diabetes or after five years in type 1. A distractor answer often substitutes serum creatinine as the screening test, which is incorrect because creatinine rises too late to catch early disease.
A second common item presents a patient with microalbuminuria and a normal blood pressure, then asks whether an ACE inhibitor order should be questioned. The correct answer recognizes the drug is appropriate regardless of blood pressure, testing the same fact this page leads with. Expect related items on monitoring potassium after starting these drugs and on recognizing NSAIDs as a risk to a kidney already under strain.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our endocrine practice questions are the closest set to what this page covers.
Common questions
Why is microalbuminuria checked instead of just monitoring creatinine?
Creatinine only rises once significant kidney damage has already occurred, while microalbuminuria appears years earlier as the glomeruli first start leaking protein. Screening with the urine albumin-to-creatinine ratio catches the disease at a stage where intervention can still slow its progression.
If blood pressure is normal, why start an ACE inhibitor?
ACE inhibitors and ARBs lower pressure inside the glomerulus itself, reducing protein leakage and slowing kidney damage independent of their effect on systemic blood pressure. This renal-protective effect is why the drug is started based on the microalbuminuria finding, not the blood pressure reading.
What lab value needs monitoring after starting an ACE inhibitor in this population?
Potassium. Both ACE inhibitors and ARBs can cause hyperkalemia, and the risk is higher when kidney function is already reduced, so a baseline and follow-up potassium level are standard after starting or adjusting the dose.
Are NSAIDs really a concern for a patient with diabetic nephropathy?
Yes. NSAIDs reduce blood flow to the kidneys and can accelerate decline in a patient whose renal reserve is already compromised. Patients should be taught to avoid over-the-counter NSAIDs for routine pain and to check with the provider before using them.